



PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

1631

# TRANSMITTAL FORM


(To be used for all correspondence after initial filing)

Application Number	09/827,271
Filing Date	April 4, 2001
First Named Inventor	Marc W. Retter
Group Art Unit	1631
Examiner Name	
Attorney Docket No.	210121.462C6

RECEIVED

MAR 18 2003

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Supplemental Information Disclosure Statement; Form PTO-1449 <input checked="" type="checkbox"/> Cited References (8) <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts under 37 C.F.R. 1.52 or 1.53 <input type="checkbox"/> Response to Missing Parts/Incomplete Application	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Request for Corrected Filing Receipt <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation, Change of Correspondence Address <input type="checkbox"/> Declaration <input type="checkbox"/> Statement under 37 CFR 3.73(b) <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Small Entity Statement <input type="checkbox"/> Request for Refund	<input type="checkbox"/> CD(s), Number of CD(s) _____ <input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Return Receipt Postcard <input type="checkbox"/> Additional Enclosure(s) (please identify below): <hr/> <hr/> <hr/>
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Individual Name	William T. Christiansen, Ph.D. 44,614	 <b>00500</b> <small>PATENT TRADEMARK OFFICE</small>
Signature		
Date	March 12, 2003	

CERTIFICATE OF MAILING		
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date specified below.		
Typed or printed name	Lawrence Teague	
Signature		Date: March 12, 2003



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Marc W. Retter and Gary R. Fanger  
Application No. : 09/827,271  
Filed : April 4, 2001  
For : COMPOSITIONS AND METHODS FOR THE THERAPY AND  
DIAGNOSIS OF OVARIAN CANCER

Art Unit : 1631  
Docket No. : 210121.462C6  
Date : March 12, 2003

RECEIVED

MAR 17 2003

TECH CENTER 1600/2900

Commissioner for Patents  
Washington, DC 20231

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached form PTO-1449 (copies of the cited references are enclosed). As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Second Supplemental Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Respectfully submitted,  
Seed Intellectual Property Law Group PLLC



William T. Christiansen, Ph.D.  
Registration No. 44,614

JEH:jt

Enclosures:

Postcard  
Form PTO/SB/21  
Form PTO-1449  
Cited References (8)

701 Fifth Avenue, Suite 6300  
Seattle, Washington 98104-7092  
Phone: (206) 622-4900  
Fax: (206) 682-6031

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			ATTY. DOCKET NO. <b>210121.462C6</b>	APPLICATION NO. <b>09/827,271</b>
<b>SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)			APPLICANTS <b>Marc W. Retter and Gary R. Fanger</b>	
			FILING DATE <b>April 4, 2001</b>	GROUP ART UNIT <b>1631</b>

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES      NO
	AB	WO 00/36107	06/22/00	WIPO	<b>RECEIVED</b>
	AC				MAR 18 2003
	AD				TECH CENTER 1600/2900

**OTHER PRIOR ART** (*Including Author, Title, Date, Pertinent Pages, Etc.*)

AE	Hovig, E. et al., "CA 125: The End of the Beginning," <i>Tumor Biology</i> 22: 345-347, 2001.
AF	O'Brien, T.J. et al., "The CA 125 Gene: A Newly Discovered Extension of the Glycosylated N-Terminal Domain Doubles the Size of This Extracellular Superstructure," <i>Tumor Biology</i> 23: 154-169, 2002.
AG	O'Brien, T.J. et al., "The CA 125 Gene: An Extracellular Superstructure Dominated by Repeat Sequences," <i>Tumor Biology</i> 22: 348-366, 2001.
AH	Schummer, M. et al., "Comparative hybridization of an array of 21 500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas," <i>Gene</i> 238: 375-385, 1999.
AI	Whitehouse, C. et al., "NBR1 interacts with fasciculation and elongation protein zeta-1 (FEZ1) and calcium and integrin binding protein (CIB) and shows developmentally restricted expression in the neural tube," <i>Eur. J. Biochem.</i> 269: 538-545, 2002.
AJ	Yin and Lloyd, "Molecular Cloning of the CA125 Ovarian Cancer Antigen. Identification as a new mucin, MUC16," <i>Journal of Biological Chemistry</i> 276(29): 27371-27375, July 20, 2001.
AK	Yin, B.W.T. et al., "Ovarian cancer antigen CA125 is encoded by the <i>MUC16</i> mucin gene," <i>International Journal of Cancer</i> 98: 737-740, 2002.

EXAMINER	DATE CONSIDERED
* EXAMINER:	Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).